Investors Entangled in Gossamer Bio's Class Action: Key Deadline Approaching

Class Action Alert: Gossamer Bio Investors Take Note

Investors in Gossamer Bio, Inc. (NASDAQ: GOSS), find themselves at a critical juncture as a securities class action lawsuit has been initiated against the company and one of its executives. This action seeks to represent investors who purchased Gossamer's securities during a specific period spanning from June 16, 2025, to February 20, 2026. Key developments in the case demand attention, particularly given the recent upheaval surrounding the company's Phase 3 PROSERA trial results.

Background of the Case

On February 23, 2026, Gossamer announced disappointing results from its key Phase 3 PROSERA study, aimed at evaluating the efficacy of seralutinib for the treatment of pulmonary arterial hypertension (PAH). The trial's failure to meet its primary endpoint—a significant reduction in six-minute-walk distance after 24 weeks—sent shockwaves through the investor community, leading to an immediate 80% drop in the company's stock price.

This significant downturn has prompted the law firm Hagens Berman to launch an investigation into Gossamer's practices, with a strong emphasis on potential violations of federal securities laws. Their inquiry particularly scrutinizes Gossamer's disclosures related to the trial's design and the recruitment of patients, as the allegations indicate mismanagement of expectations about the drug's potential.

Allegations and Investor Impact

The core of the lawsuit revolves around claims that Gossamer did not adequately inform investors of known issues with the PROSERA trial design, thereby misleading them about the viability of seralutinib. Analysis indicates that many patients involved in the study, particularly from Latin America, were heavily treated and may have skewed the results positively, which created an artificially optimistic narrative about the expected outcomes.

Statements made by Gossamer’s management prior to the trial's results further compound allegations of misleading communication. They touted seralutinib as a